Literature DB >> 19285285

Safeguarding against substandard/counterfeit drugs: mitigating a macroeconomic pandemic.

Albert I Wertheimer1, Jeremiah Norris.   

Abstract

BACKGROUND: Counterfeiting and the sale of substandard pharmaceutical products can no longer be ignored. At 10% of global trade, counterfeiting is affecting many countries, causing serious downstream expenses and resource shortages.
OBJECTIVE: To describe the nature and impact of drug product counterfeiting and substandard product sale and to present strategies that may have value in ameliorating these phenomena.
METHODS: A literature review was conducted, supplemented by interviews of key leaders/experts in the field and the search of relevant web sites. All of the data were combined, integrated, and coordinated to present the complete picture of this problem.
RESULTS: In addition to known corruption in some of the least developed countries, the trail through developed countries was detected. This report identifies means to detect faulty products and describes efforts toward resisting and ending these corrupt practices.
CONCLUSIONS: Counterfeit drugs, if not stopped, can be responsible for a macroeconomic pandemic where major portions of some populations may be too ill to work and where the health sector resources are completely overwhelmed, as with the case of HIV/AIDS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19285285     DOI: 10.1016/j.sapharm.2008.05.002

Source DB:  PubMed          Journal:  Res Social Adm Pharm        ISSN: 1551-7411


  12 in total

1.  Counterfeit medicines in Cambodia--possible causes.

Authors:  Mohiuddin Hussain Khan; Junko Okumura; Tey Sovannarith; Nam Nivanna; Hiroto Nagai; Masatoshi Taga; Naoko Yoshida; Manabu Akazawa; Tsuyoshi Tanimoto; Kazuko Kimura
Journal:  Pharm Res       Date:  2010-10-01       Impact factor: 4.200

2.  Pill characterization data streams for reducing exposure to inadequately identified anti-malarial medication in developing countries.

Authors:  Peter Pennefather; Aria Ilyad Ahmad; Ian Crandall; West Suhanic
Journal:  Malar J       Date:  2010-07-22       Impact factor: 2.979

Review 3.  Substandard/counterfeit antimicrobial drugs.

Authors:  Theodoros Kelesidis; Matthew E Falagas
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

4.  How pharmaceutical industry employees manage competing commitments in the face of public criticism.

Authors:  Wendy Lipworth; Kathleen Montgomery; Miles Little
Journal:  J Bioeth Inq       Date:  2013-06-07       Impact factor: 1.352

5.  Chronic kidney disease in low- and middle-income countries.

Authors:  John W Stanifer; Anthony Muiru; Tazeen H Jafar; Uptal D Patel
Journal:  Nephrol Dial Transplant       Date:  2016-02-04       Impact factor: 5.992

6.  Variable-pitch rectangular cross-section radiofrequency coils for the nitrogen-14 nuclear quadrupole resonance investigation of sealed medicines packets.

Authors:  Jamie Barras; Shota Katsura; Hideo Sato-Akaba; Hideo Itozaki; Georgia Kyriakidou; Michael D Rowe; Kaspar A Althoefer; John A S Smith
Journal:  Anal Chem       Date:  2012-10-26       Impact factor: 6.986

7.  Substandard and counterfeit medicines: a systematic review of the literature.

Authors:  Tariq Almuzaini; Imti Choonara; Helen Sammons
Journal:  BMJ Open       Date:  2013-08-17       Impact factor: 2.692

8.  Medicine procurement in hospital pharmacies of Nepal: A qualitative study based on the Basel Statements.

Authors:  Mina Shrestha; Rebekah Moles; Eurek Ranjit; Betty Chaar
Journal:  PLoS One       Date:  2018-02-05       Impact factor: 3.240

9.  Anti-counterfeit technologies: a pharmaceutical industry perspective.

Authors:  Dipika Bansal; Swathi Malla; Kapil Gudala; Pramil Tiwari
Journal:  Sci Pharm       Date:  2012-10-09

Review 10.  Substandard drugs: a potential crisis for public health.

Authors:  Atholl Johnston; David W Holt
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.